NICE nixes AstraZeneca's Lynparza; Faes sets China marketing deal; Sanofi faces ERISA suit over alleged kickbacks;

> England's cost-effectiveness gatekeepers at the National Institute for Health and Care Excellence rejected AstraZeneca's ($AZN) new ovarian cancer drug Lynparza in preliminary guidance, saying it costs too much for the benefits it provides. Release | Report

> Spain's Faes Farma inked a deal with Chinese drugmaker Eddingpharma on a joint venture that will market products in China, beginning with four of Faes' drugs. Report

> A combo of two Genentech drugs, Perjeta and Herceptin, helped breast cancer patients live longer without their disease recurring compared with Herceptin plus chemo. Story

> Stockholders in Sanofi's ($SNY) group savings plan allege that the plan's administrators violated retirement plan laws by providing misledaing information about the company's alleged kickbacks to doctors, subject of a whistleblower lawsuit. Report

And Finally... Doctors are growing increasingly impatient with cancer drug shortages. Report

Suggested Articles

Opdivo's wins in front-line gastric and esophageal cancers comes a year after Merck's Keytruda flopped in the same setting.

AstraZeneca partners with actor and asthma sufferer Tony Hale to raise awareness about eosinophilic asthma and blood testing to diagnose it.

Even at its maximum, Roche's oral Evrysdi comes at a discount to Spinraza's low-end, maintenance list price.